You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

108 search results for: type 2 inflammation

The Path to Nodules: <b>Type</b> <b>2</b> <b>Inflammation</b> at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

11 min

Type 2 Inflammation

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

<b>Type</b> <b>2</b> <b>Inflammation</b> in Atopic Dermatitis and Food Allergy

expert video

Type 2 Inflammation in Atopic Dermatitis and Food Allergy

1 min

Type 2 Inflammation

Watch this brief video as Dr. Peter Lio discusses the role of type 2 inflammation in the development of AD and food allergy.

expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

42 min

Pulmonology

Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

<b>Type</b> <b>2</b> <b>Inflammation</b> and Airway Remodeling Drive Lung Function Decline

videoanimation

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

4 min

Pulmonology

Explore the impact of type 2 inflammation and airway remodeling on lung function decline in asthma.

expert video

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

15 min

Dermatology

In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.

<b>Type</b> <b>2</b> <b>Inflammation</b> Digital Assessment Tool

interactivity

Type 2 Inflammation Digital Assessment Tool

4 min

Pulmonology

Learn how to assess patients for the presence of uncontrolled asthma driven by underlying type 2 inflammation.

Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Prurigo Nodularis Part 1: Overview of <b>Type</b> <b>2</b> <b>Inflammation</b>

expert video

Role of Type 2 Inflammation in Prurigo Nodularis Part 1: Overview of Type 2 Inflammation

8 min

Dermatology

Join Dr. Raj Chovatiya as he provides an overview of the impact of type 2 inflammation in prurigo nodularis in the first part of this discussion.

The Pathophysiology of <b>Type</b> <b>2</b> <b>Inflammation</b> in CRSwNP

interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

5 min

Rhinology

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP

Connecting <b>Type</b> <b>2</b> <b>Inflammation</b> to CRSwNP

expert video

Connecting Type 2 Inflammation to CRSwNP

1 min

Rhinology

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

<b>Type</b> <b>2</b> <b>Inflammation</b> Mediates Severe Asthma in Pediatric Patients

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Blisters and Beyond: Autoimmunity Meets <b>Type</b> <b>2</b> <b>Inflammation</b> in Bullous Pemphigoid

expert video

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

12 min

Dermatology

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region